Skip to content

Evaluation of PV-1 as a marker of intestinal permeability in patients with liver cirrhosis

Evaluation of PV-1 as a marker of intestinal permeability in patients with liver cirrhosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00038306
Enrollment
25
Registered
2026-03-03
Start date
2026-01-26
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal permeability in liver cirrhosis K74.6

Interventions

Group 1: All patients undergo a multisugar test. A single blood and urine sample is required from the test subjects for the examinations. Once the participant has had sufficient time to consider parti

Sponsors

Medizinische Klinik III, Universitätsklinikum Aachen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Cirrhosis of the liver, defined by clinical, laboratory, or histological criteria. 2. Ascites °2 or °3 within the last 7 days 3. Hospitalization at the time of study inclusion

Exclusion criteria

Exclusion criteria: 1. Hepatocellular carcinoma (HCC) outside Milan or extrahepatic malignancy 2. Pregnancy or breastfeeding 3. Condition after TIPS placement 4. Hypersensitivity or allergies to sucrose, rhamnose, sucralose, erythritol, or lactulose. 5. Hereditary fructose intolerance 6. Presence of an existing or concomitant disease or general health condition that, in the opinion of the investigator, poses an unacceptable risk for participation in the study 7. Lactulose treatment within the last 72 hours.

Design outcomes

Primary

MeasureTime frame
1. Evidence of a significantly higher PV-1 concentration in patients with an elevated IP index (>median) compared to patients with a lower IP index (=median) 2. Transplant-free 90-day survival rate depending on the serum concentration of PV-1

Secondary

MeasureTime frame
1. Occurrence of spontaneous bacterial peritonitis within 90 days 2. Occurrence of hospitalizations within 90 days 3. Occurrence of renewed decompensation within 90 days

Countries

Germany

Contacts

Public ContactTony Bruns

Medizinische Klinik III, Universitätsklinikum Achen

tbruns@ukaachen.de0241 80 80866

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026